Catalent to provide fill and finish services for Samsung bioepis’ biosimilar therapy

Provider of advanced delivery technologies, Catalent Pharma Solutions, has announced it will provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel, which is used to treat five chronic diseases.

Catalent will provide the service for Korean-based biopharmaceutical company, Samsun Bioepis at its facility in Brussels, Belgium.

The biosimilar as Benepali, is used in the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis. It is the first etanercept biosimilar to receive regulatory approval by the European Commision (EC).

 Jonathan Arnold, vice president & general manager, Drug Delivery Solutions at Catalent said: “We are proud to have partnered with Samsung Bioepis on the launch of this biosimilar therapy, which was the first etanercept biosimilar to receive European Commission approval, and look forward to a continued partnership as we continue to commercial supply.”